0 التعليقات
0 المشاركات
210 مشاهدة
0 معاينة
البحث
إكتشاف أشخاص جدد وإنشاء اتصالات جديدة وصداقات جديدة
-
الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
-
VEGF Inhibitors for Cancer Market Growing at 7.3% CAGR Amid Rising Targeted Oncology TherapiesAccording to a new report from Intel Market Research, the global VEGF Inhibitors for Cancer market was valued at USD 8.42 billion in 2025 and is projected to reach USD 15.67 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2026–2034). This growth trajectory reflects the increasing adoption of targeted therapies in oncology and significant advancements in angiogenesis...0 التعليقات 0 المشاركات 8كيلو بايت مشاهدة 0 معاينة
-
Basal Cell Carcinoma Therapeutics Market to Reach USD 14.6 Billion by 2032 | CAGR 7.3%According to a newly published market research report by 24LifeSciences, global basal cell carcinoma therapeutics market was valued at USD 8.2 billion in 2024 and is projected to reach USD 14.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.3% during the forecast period 2025-2032. Basal Cell Carcinoma (BCC), the most common form of skin cancer accounting for...0 التعليقات 0 المشاركات 5كيلو بايت مشاهدة 0 معاينة
-
Bladder Cancer Market to Reach USD 4.1 Billion by 2031 | CAGR 6.7%According to a newly published market research report by 24LifeSciences, global bladder cancer market was valued at USD 2.6 billion in 2024 and is projected to reach USD 4.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.7% during the forecast period 2025-2031. Bladder cancer remains one of the most prevalent urological malignancies worldwide, with non-muscle invasive...0 التعليقات 0 المشاركات 2كيلو بايت مشاهدة 0 معاينة
-
Bone Metastasis Therapeutics Market Growth & CAGR 8.3% ForecastAccording to a newly published market research report by 24LifeSciences, global bone metastasis therapeutics market was valued at USD 2.5 billion in 2024 and is projected to reach USD 4.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the forecast period 20252031. Bone metastasis therapeutics comprise a critical class of treatments designed to manage secondary...0 التعليقات 0 المشاركات 1كيلو بايت مشاهدة 0 معاينة
-
Bone Metastasis Therapeutics Market Growth & CAGR 8.3% ForecastAccording to a newly published market research report by 24LifeSciences, global bone metastasis therapeutics market was valued at USD 2.5 billion in 2024 and is projected to reach USD 4.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the forecast period 20252031. Bone metastasis therapeutics comprise a critical class of treatments designed to manage secondary...0 التعليقات 0 المشاركات 1كيلو بايت مشاهدة 0 معاينة
-
Carfilzomib Market Expands with 7.5% CAGR Driven by Advances in Multiple Myeloma TherapiesAccording to a new report from Intel Market Research, the global Carfilzomib market was valued at USD 1.45 billion in 2025 and is projected to reach USD 2.89 billion by 2034, growing at a steady CAGR of 7.5% during the forecast period (2025–2034). This growth reflects the expanding clinical application of Carfilzomib in treating relapsed/refractory multiple myeloma, coupled with rising...0 التعليقات 0 المشاركات 4كيلو بايت مشاهدة 0 معاينة1
-
Epidermal Growth Factor Receptor Inhibitor Market Strategic Insights for Leading CompaniesThe global Epidermal Growth Factor Receptor (EGFR) inhibitor industry is witnessing substantial momentum due to the increasing prevalence of cancer, growing adoption of targeted therapies, and advancements in precision medicine. The Epidermal Growth Factor Receptor Inhibitor Market size is expected to reach US$ 32.14 Billion by 2034 from US$ 15.92 Billion in 2025. The market is estimated to...0 التعليقات 0 المشاركات 476 مشاهدة 0 معاينة
-
Global BRAF Kinase Inhibitors Market to Reach USD 3.78 Billion by 2034 Amid Rising Precision Oncology AdoptionAccording to a new report from Intel Market Research, the global BRAF kinase inhibitors market was valued at USD 1.85 billion in 2025 and is projected to reach USD 3.78 billion by 2034, growing at a CAGR of 7.5% during the forecast period (2026–2034). This growth trajectory reflects the expanding applications of BRAF inhibitors in precision oncology and the increasing prevalence of...0 التعليقات 0 المشاركات 3كيلو بايت مشاهدة 0 معاينة
-
Global Endometrial Cancer Treatment Market Insights & Growth Trends | CAGR 4.5% (2025–2031)According to a newly published market research report by 24LifeSciences, global endometrial cancer treatment market was valued at USD 21,380 million in 2024 and is projected to reach USD 28,790 million by 2031, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period 2025–2031. Endometrial cancer, classified under gynecologic malignancies, originates in the...0 التعليقات 0 المشاركات 1كيلو بايت مشاهدة 0 معاينة1
-
Global Endometrial Cancer Treatment Market Insights & Growth Trends | CAGR 4.5% (2025–2031)According to a newly published market research report by 24LifeSciences, global endometrial cancer treatment market was valued at USD 21,380 million in 2024 and is projected to reach USD 28,790 million by 2031, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period 2025–2031. Endometrial cancer, classified under gynecologic malignancies, originates in the...0 التعليقات 0 المشاركات 1كيلو بايت مشاهدة 0 معاينة1
-
HDAC Inhibitor Market Outlook Across Oncology and Therapeutic ApplicationsThe global HDAC inhibitor market is gaining significant momentum as the healthcare industry continues to advance targeted therapies for cancer and other complex diseases. Histone deacetylase (HDAC) inhibitors are a class of compounds that regulate gene expression by altering chromatin structure, making them valuable in the treatment of various malignancies and epigenetic disorders. The...0 التعليقات 0 المشاركات 471 مشاهدة 0 معاينة
-
Imatinib Drug Market Dynamics and Long-Term Growth PotentialThe global imatinib drug market continues to play a crucial role in the oncology sector due to the widespread use of imatinib in targeted cancer therapies. As one of the pioneering tyrosine kinase inhibitors, imatinib has significantly transformed the treatment landscape for specific cancers by offering targeted therapeutic benefits. The drug remains an important treatment option in various...0 التعليقات 0 المشاركات 582 مشاهدة 0 معاينة
الصفحات المعززة